Diabetes PubMed

The overall attitude on the artificial pancreas (AP) was positive. Intention to use was dependent on trust in the AP, which was related to the quality of glucose control provided by the AP.

These results demonstrate the feasibility of safe blood glucose (BG) control by a bihormonal artificial endocrine pancreas.

It is our opinion that, in order to support the rapid development of an artificial pancreas for patients with diabetes, adequate action to lower this hurdle should be undertaken by a consortium of all parties involved (industries, patient organizations, health-care professionals, and institutional payers).

The artificial pancreas shows promise for use as insulin treatment for patients with pancreatogenic diabetes after pancreatic resection.

Considering the increasing requirement for tight perioperative glycemic control and the recognized risk of hypoglycemia, we propose the use of an artificial endocrine pancreas that is able to monitor continuously blood glucose concentrations with proven accuracy, and administer automatically substances to return blood glucose concentration to the optimal narrow range.